Universitè De Montpellier

Institut Regional Du Cancer De Montpellier

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Inserm (institut National De La Sante Et De La Recherche Medicale)

Sorbonne Université

Université Paris Diderot-paris 7

Centre National De La Recherche Scientifique-cnrs

Institut Pasteur De Lille

Université De Paris

Université De Lille

Bio-rad Pasteur

Institut Jean Godinot

Institut Régional Du Cancer De Montipellier

Inserm

Pierre Martineau

Bruno Robert

Myriam Chentouf

Armand Bensussan

Christel Larbouret

André Pelegrin

Thierry Chardes

Franck Molina

Philippe Gosset

Marie-Alix Poul

Muriel Pichavant

Alain Couvineau

Thierry Voisin

Piona Dariavach

Pascal Nicole

Nathalie Di Clemente-Besse

Yahya Ashraf

Karine Piot

Claire Lamoure

Anne Marie-Cardine

Mélina Le Roux

Maëva Chauvin

Jérôme Giustiniani

Emmanuelle Liaudet-Coopman

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected byand protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease

In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.

Anti-müllerian inhibiting substance antibodies and uses thereof

The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

Monoclonal antibodies binding to the CD160 transmembrane isoform

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.

Human monoclonal antibodies against orexin receptor type 1

The invention relates to human anti-Cath-D neutralizing monoclonal antibodies and uses thereof. More particularly, the invention relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an isolated human monoclonal antibody or a fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.

Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor

The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

Human monoclonal antibodies against AXL

The invention concerns a method for identifying a ligand capable of selectively modulating a functional cascade involving a target, and uses thereof for high-throughput screening of molecules of interest, in particular therapeutic (medicine). Said method comprises at least the following steps: a) identifying an antibody or an antibody fragment comprising at least one of the variable domains of an immunoglobulin chain, capable of binding to said target and modulating said functional cascade involving said target; b) screening from a bank of molecules, ligands modulating the bond between said target and the antibody or antibody fragment identified in a); and c) identifying among said modulating ligands obtained in b), those capable of modulating said functional cascade.

Method for identifying a ligand capable of selectively modulating a functional cascade involving a target, and uses thereof for high-throughput screening of molecules of interest

In order to estimate the size of an initial population of nucleic acids in a sample of interest, in particular by PCR, the following steps are performed:

Method, an installation, and a computer program for estimating the initial size of a population of nucleic acids, in particular by PCR

Growing community of inventors

Montpellier, France

Pierre Martineau